Speciality Medicines IPO
Speciality Medicines IPO Listing Day Performance
Speciality Medicines listed on BSE SME on 30 March 2026 at ₹124.00, a 0% premium over the issue price of ₹124. A retail investor allotted the minimum application of 2,000 shares (2 lots) gained ₹0 at the listing price.
GMP vs actual listing
| Last GMP before listing | ₹0 (+0%) |
| GMP-implied listing | ₹124 |
| Actual listing | ₹124.00 |
| Difference | +₹0 (+0%) |
Demand going into listing
| Subscribed overall | 2.34× |
| QIB | 96.24× |
| NII | 2.01× |
| Retail | 0.85× |
Market Sentiment
IPO Details
Day-wise Subscription (times subscribed)
| Category | Day 1 | Day 4 | Final | Final | Final | Final | Final | Final | Day 11 |
|---|---|---|---|---|---|---|---|---|---|
| QIB | 1.00x | 1.00x | 96.24x | 96.24x | 96.24x | 96.24x | 96.24x | 96.24x | 96.24x |
| NII | 1.41x | 1.60x | 1.77x | 1.77x | 1.77x | 1.77x | 1.77x | 1.77x | 2.01x |
| bNII > ₹10L | 2.37x | 2.68x | 2.70x | 2.70x | 2.70x | 2.70x | 2.70x | 2.70x | 2.70x |
| sNII 2-10L | 0.06x | 0.10x | 0.64x | 0.64x | 0.64x | 0.64x | 0.64x | 0.64x | 0.64x |
| Retail | 0.07x | 0.19x | 0.85x | 0.85x | 0.85x | 0.85x | 0.85x | 0.85x | 0.85x |
| Total | 0.78x | 0.94x | 2.19x | 2.19x | 2.19x | 2.19x | 2.19x | 2.19x | 2.34x |
Market Lot Size
IPO Reservation
Financial Analysis
Financial Data
Financial Performance
| Metric | 2024 | 2025 | Oct 2025 |
|---|---|---|---|
| Revenue | 27.66 | 58.54 | 36.93 |
| Expense | 23.10 | 49.85 | 30.80 |
| Profit (PAT) | 2.93 | 8.61 | 6.06 |
| Total Assets | 22.68 | 39.98 | 45.57 |
Peer Comparison
| Company | EPS | P/E | Market Cap (Cr) |
|---|---|---|---|
| Remus Pharmaceuticals Limited | 65.21 | 12.25 | 15 |
| Trident Lifeline Limited | 10.22 | 27.59 | 18 |
| Mono Pharmacare Limited | 1.75 | 13.87 | 10 |
Promoters & Holding Pattern
Promoters: Parth B Goyani and Goyani Sumit Babubhai
| Shareholding | No. of Shares | Holding % |
|---|---|---|
| Promoter Holding Pre Issue | 64,35,796 | 59.28% |
| Promoter Holding Post Issue | 87,85,796 | 43.44% |
Strengths & Risks
- Strong institutional (QIB) demand — 96.2x.
- Revenue grew 112% in the latest reported year.
- Solid profit margin — 14.7%.
- Strong return on equity — 38%.
- Low leverage — debt/equity of 0.17.
- Promoter stake drops to 43% after the issue.
- Lists on the exchange's SME platform, where trading is usually thinner than on the main board — selling at your price can be harder.
From this issue's live data. Not investment advice — read the RHP.
Company Information
Speciality Medicines at a glance
From the company's description: “One of the leading companies,” Speciality Medicines” was founded in 2021 and started a business of marketing and distribution of finished formulations of specialty pharmaceutical products, comprising high-cost oral and injectable medications used in the treatment of complex and chronic…”
Speciality Medicines is raising ₹29.14 crore through an IPO on the BSE SME. All of it is a fresh issue: there is no offer for sale, so every rupee raised goes to the company rather than to selling shareholders. Main stated uses of the fresh money: Setting up of the Research and Development (R&D) Centre (₹13.31 crore), To Meet Working Capital Requirements (₹12 crore) and Product registration in the international markets (₹2.89 crore).
Revenue went from ₹27.66 crore in 2024 to ₹58.54 crore in 2025, up 112% over 1 year. Profit after tax went from ₹2.93 crore to ₹8.61 crore, a net margin of 15% in the latest year.
The promoter, Parth B Goyani and Goyani Sumit Babubhai, holds 59% before the issue and 43% after it — a dilution of 15.8 percentage points. Debt stands at 0.17 times equity.
Written from the issue's offer-document figures shown on this page. Not investment advice.
Company Contact Information
Speciality Medicines Ltd., 913, One World West, S. No. 396, FP 119,, Village- Vejalpur, Ahmadabad City,, Ahmedabad, Gujarat, India,, Ahmedabad, Gujarat, 380051
Objects of the Issue
| Purpose | Amount (Cr) |
|---|---|
| Setting up of the Research and Development (R&D) Centre | 13.31 |
| Product registration in the international markets | 2.89 |
| Repayment/ Prepayment, in full or part, of certain borrowings availed by the Company | 1.75 |
| To Meet Working Capital Requirements | 12.00 |
| General Corporate Purpose | - |
Resources & Documents
IPO Documents
Draft Red Herring ProspectusSpeciality Medicines IPO - Quick Take
Speciality Medicines has set a price band of Rs 117–Rs 124 per share for an issue size of Rs 29 crore. The stock listed flat against its issue price.
The issue is promoted by Parth B Goyani and Goyani Sumit Babubhai with Unicon Capital Services Pvt. Ltd. acting as lead manager. Net proceeds will primarily be used towards setting up of the Research and Development (R&D) Centre (Rs 13 crore) and product registration in the international markets (Rs 3 crore).
On fundamentals, the company is posting revenue growth of 111.6%, a profit margin of 14.7%, return on equity of 37.9% in its most recent reported period. Listed peers in this segment include Trident Lifeline Limited (P/E 27.59x, market cap Rs 18 crore) and Remus Pharmaceuticals Limited (P/E 12.25x, market cap Rs 15 crore) — useful reference points when evaluating the issue's pricing relative to where the broader sector is trading.
On our data-signal score, the combined signals for this issue currently read mixed — some indicators read positively and others do not. This is a summary of public data, not a recommendation to apply or skip. Past performance does not predict future returns — review the price chart and peer comparison below before trading.
Speciality Medicines IPO: Lead Manager & Registrar Track Record
How the firm running this issue and its registrar have fared on the other IPOs we track. Each firm's figures leave out Speciality Medicines itself, so they describe what came before it.
- Speciality Medicines listed at +0% on day one; the median of 193 listings was +1.7% (better than 30% of them).
- Subscribed 2.34x against a median of 4.03x across 192 issues (higher than 40%).
- Average listing-day move across all 194 SME listings we track: +11.6%.
| Firm | Other IPOs | Listed at / above issue | Avg move | Median |
|---|---|---|---|---|
| Unicon Capital Services Pvt. Ltd. Lead manager | 1 1 MB · 0 SME | 100% 1 of 1 | +65.3% | +65.3% |
| Skyline Financial Services Pvt. Ltd. Registrar | 16 0 MB · 16 SME | 69% 11 of 16 | Check allotment → | |
Recent listings managed by Unicon Capital Services Pvt. Ltd. (1)
| IPO | Listed | Listing-day move |
|---|---|---|
| BLS Polymers | 03 Nov 2026 | +65.3% |
A SEBI-registered merchant banker that runs the issue: due diligence, drafting the offer document, setting the price band with the company, and marketing the IPO to investors.
Finalises the basis of allotment, credits shares to demat accounts, releases blocked funds for unsuccessful bids and handles investor queries about the issue.
Listing-day move = exchange opening price vs issue price (band ceiling where the final price isn't recorded). Counts cover IPOs we track only. Past listings don't predict this one; this is not investment advice.
Frequently Asked Questions
Speciality Medicines IPO GMP — What It Means
See the full Speciality Medicines GMP history and trend, or learn how grey market premium works and how reliable it is.
Related IPO
Same sector or same stage as Speciality MedicinesNo comments yet. Be the first to share your opinion!